Press Release

KDA GROUP GRANTS STOCK OPTIONS

Thetford Mines, Quebec – February 18, 2021 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”) announces that, pursuant to its stock option plan, it has granted incentive stock options to directors, officers, employees and consultants of the Corporation to purchase up to an aggregate of 7,000,000 Class A shares (the “Common shares”). 

KDA Group amends stock option plan and issues shares to two officers

Thetford Mines, Quebec – January 7, 2021 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”) announces that it has approved an amendment to its stock option plan (the ”Stock Option Plan”) in order to increase the number of class A shares (“Common Shares”) that may be issued pursuant to the exercise of options under the Stock Option Plan from 8,477,551 to 25,284,189 being 20% of the Corporation’s issued and outstanding Common Shares.

KDA Group modifies its strategic advisory board

Thetford Mines, Quebec – December 9, 2020 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”) is pleased to announce the new composition of its Strategic Advisory Board (the “Strategic Board”) with the addition of Messrs. Denis Gadbois, Yves Salembier and Dr. Shane Morris.

KDA Group annouces closing of private placement

Thetford Mines, Quebec – November 25, 2020 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”) is pleased to announce the closing of a private placement with accredited investors totaling 8,000,000 units (the “Units”) at a price of $0.15 per Unit for total gross proceeds of $1,200,000 (the “Private Placement”).

KDA Group has signed an exclusive letter of intent to acquire tu ZRx prescriber technology asset for development and operation in the United States and Europe

Thetford Mines, Quebec – November 18, 2020 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”) is pleased to announce that the Corporation has signed an exclusive Letter of Intent (the “LOI”) with ZoomMed Medical Inc. (“ZoomMed Medical”) for the acquisition of the ZRx Prescriber technology asset consisting of its platform and source codes (the “ZRx Prescriber Asset”). KDA aims to develop and use the ZRx Prescriber Asset in the United States and Europe.

KDA Group amends the expiry date of 1,890,333 warrants

Thetford Mines, Quebec – October 16, 2020 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”) announces that it proposed to amend the expiry date of 13,890,333 warrants to purchase 13,890,333 Class A Shares of KDA (the “Common shares”) at a price of $0.20 per Common share from November 7, 2020 to November 7, 2021 as permitted under the TSX Venture Exchange (“TSXV”) Policy.

Groupe KDA © 2019  |  Tous droits réservés